司美格鲁肽、替尔泊肽或对女性更有效！研究人员正在挖掘背后原因

Core Insights - Recent clinical trial results indicate that injectable GLP-1 medications show better average weight loss effects in women compared to men, which is contrary to historical trends where men typically respond better to dieting and exercise [2][3]. Group 1: Clinical Trial Findings - A study presented at the European Obesity Congress and published in the New England Journal of Medicine compared two GLP-1 drugs: Semaglutide (Wegovy) and Tirzepatide (Zepbound) [5]. - Approximately 750 obese patients were divided into two groups, receiving the maximum tolerated doses of either Wegovy or Zepbound [5]. - Participants taking Zepbound lost about 50% more weight on average compared to those taking Wegovy, confirming Zepbound's superior efficacy [5]. Group 2: Gender Differences in Weight Loss - In previous long-term trials, women taking Semaglutide lost approximately 11% of their body weight, while men lost about 8% [7]. - In the Tirzepatide study, women lost up to 28% of their body weight, compared to men who lost up to 19% [7]. - Factors contributing to these differences may include dosage, as women typically weigh less but receive the same drug dosage, potentially leading to a stronger effect [8]. Group 3: Biological and Behavioral Factors - Behavioral and social factors may also play a role; women often face greater pressure to lose weight, which may enhance their motivation and adherence to treatment [8]. - Women are reportedly more willing to tolerate common side effects, such as nausea and vomiting, compared to men, who may discontinue treatment earlier [8][9]. Group 4: Hormonal Influences - Research indicates that estrogen, more prevalent in women, may enhance the effects of GLP-1 on appetite control and reward behavior [11]. - Studies in animal models suggest that estrogen can increase the number of hormone receptors, thereby amplifying GLP-1's effects [11]. Group 5: Future Research Directions - There is a need for more research to understand the underlying reasons for gender differences in GLP-1 responses, as many clinical trials do not report results by gender [13]. - Understanding these mechanisms could lead to improved treatment strategies, suggesting that men may require different dosing strategies or adjunct medications [15].